A major medical journal is asking which patients should be screened for a common but frequently undetected liver condition that affects nearly a third of all adults globally.
—
A Silent Condition Hidden in Plain Sight
Picture a condition so common it affects roughly one in every three adults on the planet — and yet most people who have it don’t know. That’s the reality with metabolic dysfunction-associated steatotic liver disease, known as MASLD. The New England Journal of Medicine has posted about the condition on social media, raising a question that’s becoming increasingly urgent for clinicians and patients alike: who should actually be screened for it?
MASLD is a form of liver disease linked to metabolic health — think obesity, type 2 diabetes, and high cholesterol. It’s what used to be called non-alcoholic fatty liver disease, though the name has been updated to better reflect what’s actually happening in the body. Fat builds up in the liver, and over time, that can lead to inflammation, scarring, and eventually serious damage.
Why So Many Cases Go Undetected
Here’s the problem. MASLD often causes no symptoms in its early stages. None. People can be walking around with significant liver changes and feel completely fine — until they don’t. By the time many cases are picked up, the liver has already developed advanced fibrosis or cirrhosis, both of which are serious and harder to manage.
That diagnostic gap is exactly what the New England Journal of Medicine is drawing attention to. The journal’s latest episode — referenced in the post — focuses on the clinical question of which patients clinicians should be prioritising for screening, before disease reaches those later stages.
The Scale of the Problem
Nearly one in three adults worldwide. That figure, cited by the journal, puts MASLD in the same league as some of the most common chronic conditions we talk about. And unlike some diseases that cluster in specific populations, MASLD cuts across age groups and demographics — though people with obesity, type 2 diabetes, or other metabolic conditions carry a higher risk.
So the screening question isn’t academic. It has real consequences for how GPs and hospital clinicians decide who gets tested and when.
What the Medical Community Is Discussing
The New England Journal of Medicine, one of the world’s leading peer-reviewed medical publications, is actively publishing content on this topic — a sign that the conversation around MASLD is moving up the clinical agenda. The journal’s post frames it clearly: many cases remain undiagnosed until advanced fibrosis or cirrhosis develops, and that’s a problem the medical community needs to address head-on.
There are no simple answers yet. Screening guidelines vary, and the debate about who benefits most from early detection is ongoing. But the fact that a publication of this standing is highlighting the gap suggests the medical profession is taking it seriously.
—
Source: @NEJM
Key Takeaways
- MASLD (metabolic dysfunction-associated steatotic liver disease) affects nearly one in three adults worldwide, according to the New England Journal of Medicine
- Many cases go undetected until advanced liver damage — including fibrosis or cirrhosis — has already developed
- The medical community is actively debating which patients should be prioritised for screening, with no universal consensus yet established
—
What This Means for Kent Residents
If you’re living in Kent and have risk factors such as obesity, type 2 diabetes, high blood pressure, or high cholesterol, it’s worth having a conversation with your GP about your liver health — especially if it’s not something that’s come up before. NHS Kent and Medway covers a large and diverse population, and conditions like MASLD can affect people across the county without producing obvious warning signs. Don’t wait for symptoms to appear; ask your GP directly whether a liver function test or further assessment might be appropriate for you. For general health queries, you can also contact NHS 111, and in an emergency, always call 999.